The average one-year price target for Vor Biopharma (NasdaqGS:VOR) has been revised to $36.46 / share. This is an increase of 2,942.55% from the prior estimate of $1.20 dated September 10, 2025. The ...
Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...
Fintel on MSN
Baird Upgrades Vor Biopharma (VOR)
Fintel reports that on October 15, 2025, Baird upgraded their outlook for Vor Biopharma (NasdaqGS:VOR) from Neutral to ...
We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive ...
VOR Biopharma's valuation surged after in-licensing telitacicept and securing PIPE financing, but capital structure uncertainty persists. Telitacicept's positive phase 3 data in Sjögren's disease ...
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored ...
Shares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based ...
The latest price target for Vor Biopharma (NASDAQ:VOR) was reported by Baird on October 15, 2025. The analyst firm set a price target for $64.00 expecting VOR to rise to within 12 months (a possible ...
Vor Biopharma Inc. (NASDAQ:VOR), a biotechnology company with a market capitalization of approximately $199 million, announced Wednesday that it will implement a 1-for-20 reverse stock split of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback